Stock Financial Ratios


OPK / Opko Health, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.78
Volume4,283,500.00
Market Cap ($M)2,763.46
Enterprise Value ($M)3,660.98
Book Value ($M)2,091.81
Book Value / Share3.80
Price / Book1.32
NCAV ($M)2,503.32
NCAV / Share4.54
Price / NCAV1.56
Income Statement (mra) ($M)
Revenue1,221.66
EBITDA-73.28
Net Income-25.08
Balance Sheet (mrq) ($M)
Cash & Equivalents100.36
Cash / Share0.18
Assets2,721.99
Liabilities632.95
Quick Ratio1.66
Current Ratio1.84
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.01
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.01
Identifiers and Descriptors
CUSIP68375N903
Central Index Key (CIK)944809
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
68375N103
68375NAB9
301610101
68375N953
068375N10
Share Statistics
Common Shares Outstanding (M)559.40
Scoring Models
Piotroski F Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Equity Per Share3.79
Inventory Work In Progress Per Share0.00
Current Portion Of Long Term Debt Per Share0.03
Long Term Debt Per Share0.00
Liabilities Current Per Share0.47
Cash And Equivalents Per Share0.18
Treasury Stock Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Property Plant And Equipment Net Per Share0.26
Liabilities Per Share1.15
Inventory Raw Materials Per Share0.01
Accounts Receivable Per Share0.42
Intangibles Per Share0.00
Assets Other Current Per Share0.01
Liabilities Other Non Current Per Share0.41
Accumulated Depreciation And Depletion Per Share0.00
Assets Current Per Share0.78
Cash Per Share0.18
Minority Interest Per Share0.00
Additional Paid In Capital Per Share5.23
Property Plant And Equipment Gross Per Share0.00
Inventory Per Share0.09
Goodwill Per Share1.30
Debt Per Share0.03
Liabilities And Stock Equity Per Share4.94
Retained Earnings Per Share-1.44
Accounts Payable Per Share0.00
Property Plant And Equipment Per Share0.26
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Finished Goods Per Share0.04
Assets Per Share4.94
Assets Other Non Current Per Share0.07

Stock Research Report

Opko Health is a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Its diagnostics business includes BioReference Laboratories (“BioReference”), the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform (in development). Opko Health's pharmaceutical business features Rayaldee , an FDA-approved treatment for secondary hyperparathyroidism (“SHPT”) in adults with stage 3 or 4 chronic kidney disease (“CKD”) and vitamin D insufficiency (launched in November 2016), and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO in November 2015 and pending approval for IV formulation), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clini...

Click for full article

Related News Stories

OPKO Health: A House Of Cards Tumbling In The Dark

2017-11-17 seekingalpha
A slew of undisclosed or thinly disclosed executive team departures in the diagnostics division, which represents over 82.8% of revenue, could signal business decline and a compliance “house-cleaning”. (73-0)

Cramer's lightning round: Opko Health is a 'neighborhood of pain'

2017-11-16 cnbc
Opko Health Inc.: "Oh my god, the quarter, not good. I mean, this thing has become a genuine house of pain. No, this is like a neighborhood of pain. And until [CEO] Dr. Frost comes on, we're going to back away. We have to. We have to." (207-1)

What Do Versartis (NASDAQ: VSAR)'s Troubles Mean For Opko Health (NASDAQ: OPK)? | Benzinga

2017-11-16 benzinga
Versartis Inc (NASDAQ: VSAR) shares are slumping even as rival Opko Health Inc. (NASDAQ: OPK) is seeing slight strength, though not proportionate to the sell-off seen in Versartis shares. (144-2)

General Electric, Synergy Pharma Stuck Again in Tuesday’s 52-Week Low Club

2017-11-14 247wallst
November 14, 2017: Here are four stocks trading with heavy volume among 170 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners and advancers by less than 4 to 3. (333-3)

The Interesting Company That Produces An Anti-Aging Pill

2017-11-14 seekingalpha
ChromaDex has a product that can has multiple health benefits, including resistance to weight gain, improved control of blood sugar and cholesterol, reduced nerve damage, and longer lifespan. (79-0)

CUSIP: 68375N903